A Randomized Study of Vocal-cord Only vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer
VOCAL
NCT03759431
 Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Head and Neck |
Dr. Houda Bahig
Diane Trudel
514-890-8000 poste 11181
|
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
RTOG 1305
NCT02135042
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Head and Neck |
Dr. George Shenouda
Tatiana Carvalho
514-934-1934 poste 43698
|
A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
eVOLVE-HNSCC
NCT06129864
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Head and Neck |
Dr. Nathaniel Bouganim
Julie Latreille
514-934-1934 poste 38945
|
An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1
AHEAD-MERIT
NCT04534205
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Head and Neck |
Dr. Nathaniel Bouganim
Anna Lysina
514-934-1934 poste 35391
|
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer. A Phase III Randomized Controlled Trial
HN11 (SELECT)
NCT05451004
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Head and Neck |
Dr. Mathieu Leclerc
Josée Allard
418-525-4444 poste 16730
|
An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1
AHEAD-MERIT
NCT04534205
Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Head and Neck |
Dr. Khashayar Esfahani
Gervais Muhire
514-340-8222 poste 26187
|
A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC
NANORAY-312
NCT04892173
Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Head and Neck |
Dr. Khalil Sultanem
|
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma
FIERCE-HN
NCT06064877
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Head and Neck |
Dr. Nathaniel Bouganim
Julie Latreille
514-934-1934 poste 38945
|
Phase II Study: Induction Chemotherapy Followed by Transoral Robotic Surgery and Neck Dissection for Definitive Management of Oropharyngeal Squamous Cell Carcinoma.
NECTORS Trial
NCT04277858
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Head and Neck |
Dr. Nader Sadeghi
Elizabeth Beaubien
514-934-1934 pose 34974
|
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer. A Phase III Randomized Controlled Trial
HN11 (SELECT)
NCT05451004
Recruiting
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT
|
Head and Neck |
Dr. Isabelle Gauthier
Patricia Roy
819-346-1110 poste 14082
|
Groupe d'étude en oncologie du Québec